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Abstract
Introduction
The apparent diffusion coefficient (ADC) sequence is based on the diffusion properties of water
molecules within tissues and correlates with tissue cellularity. ADC may have a role in
predicting tumor grade for gliomas, and may in turn assist in identifying tumor biopsy sites.
The purpose of this investigation was to assess the competence of preoperative ADC values in
predicting tumor grades.
Methods
This was a retrospective investigation. We calculated the ADC values in the areas of greatest
restriction in solid tumor components, and we recorded the pattern of contrast enhancement.
Pathology reports masked to the imaging results were reviewed independently. We calculated
the differences in the mean values of different tumor grades and high-grade and low-grade
gliomas. A receiver operator curve (ROC) analysis assessed the predictive potential of ADC
values for low-grade gliomas.
Results
Forty-eight cases of glioma were included in our study. We noted a statistically significant
difference in the lowest mean ADC values for the tumor regions of Grade IV lesions (333.83 ±
295.47) compared with Grade I lesions (653.20 ± 145.07). On ROC analysis, we noted an area
under the curve (AUC) of 0.80 for the lowest ADC value in the whole tumor region, which was a
predictor of low-grade glioma with 95 % confidence interval (CI) of 0.675-0.926. The sensitivity
of the lowest ADC value was 84.5% for high-grade lesions.
Conclusion
Given our findings that the means of the lowest ADC value are significantly different between
low and high-grade gliomas with an AUC of 0.80 for ADC as a predictor of low-grade lesions
and a sensitivity of 84.5% for high-grade lesions, ADC values contain some predictive
properties of tumor grading. ADC values may be a valuable parameter in the assessment and
treatment of tumors.
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Introduction
Diffusion magnetic resonance imaging (dMRI) of the human brain, first described in 1985 [1],
has become an integral part of neuroimaging [1]. Apparent diffusion coefficient (ADC) is a
modality based on the diffusion properties of water molecules within tissues [2]. The diffusion
patterns of water molecules in the brain differ from true Brownian motion because water
molecules bounce, cross, and interact with many tissue components, including cell membranes,
fibers, and macromolecules [3]. Due to the heterogeneity of brain microarchitecture, normal
and diseased areas of the brain have different ADCs [2]. Tissues with higher rates of diffusion
have higher ADCs [4-5]. ADC, therefore, characterizes tissues quantitatively, and findings are
validated in several studies [6-7]. For e.g., a study in 13 patients showed regional variations in
cellularity, genetic expression, and ribonucleic acid (RNA) microarrays among regions with
different ADCs [4].
A study in 16 patients with glioma showed that ADCs were lower in the brains of patients with
glioblastoma multiforme (GBM) than Grade II astrocytoma and that ADC correlated with tumor
cellularity [8]. ADC may also be predictive of tumor grade, although additional evidence is
required [7].
GBMs are histopathologically evaluated by examining tissue samples obtained from regions of
contrast enhancement (CE) on gadolinium-enhanced, T1-weighted images [9-12]. The
sampling error of stereotactic surgery was found to be significant, leading to an
underestimation of tumor grade, especially for high-grade lesions [13-14]. If ADC, a marker of
cellularity, is predictive of tumor grade, then ADC may be useful in a more representative
sampling of tumor tissues. This study, therefore, examined preoperative diffusion-weighted
images to determine whether the ADC of gliomas correlates with the World Health
Organization (WHO) grade.
Materials And Methods
This retrospective observational study was performed at the Aga Khan University Hospital
(AKUH) in Karachi, Pakistan. The AKUH is a tertiary care hospital, accredited by the Joint
Commission for International Accreditation (JCIA) and certified by the International
Organization of Standardization (ISO), with over 43 specialties, including neurosurgery and
radiology. The study period was two years, from January 2014 through December 2015,
inclusive. Preoperative imaging and medical records were reviewed in February and March
2016. Data were reported according to Standards for the Reporting of Diagnostic Accuracy
Studies (STRAD) [15], and the study was in complete compliance with the ethical human-
subject standards of the World Medical Association Declaration of Helsinki: ethical principles
for medical research involving human subjects [16].
Inclusion/exclusion criteria
All patients with a histopathological diagnosis of glioma presenting during the study period
were included, irrespective of age, gender, and ethnicity. The study included gliomas of all
grades and cell types (astrocytomas and oligodendrogliomas). Patients with indeterminate
tumor grade or incomplete medical records and those who underwent preoperative radiology at
a site outside the AKUH were excluded.
Magnetic resonance imaging (MRI) evaluation
Contrast enhancement was used as a reference test, whereas ADC was regarded as an index test.
Gliomas were dichotomized as low (grades I and II) and high (grades III and IV) tumors
according to the WHO classification. Two investigators assessed imaging data, and a third
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independently assessed histopathologic data. Both assessments were blinded to each other.
Diffusion imaging results were analyzed using the Siemens 1.5 Tesla Work Station (Siemens,
Erlangen, Germany). The area of greatest diffusion restriction (lowest ADC) within the solid
tumor component was identified while avoiding areas of peritumoral edema. Areas of visually
obvious restricted diffusion within each tumor, defined as areas of bright signal intensity on
b1000 images and a corresponding low ADC (i.e., a dark area on the ADC map), were identified.
The first step in numeric ADC analysis was the examination of T1, T2, and post gadolinium
sequences to identify and avoid areas likely to be cystic, hemorrhagic, calcific, necrotic, or
peritumoral edema. The section with the lowest visual ADC within the remaining areas of the
tumor was identified; a spherical region of interest (ROI) of 0.16 cm2 within this section was
determined, and the ADC of this ROI was recorded. If the area of low ADC was large, the ROI
was moved slightly within this area to determine the lowest ADC. The minimum ADC
throughout the entire tumor and the mean ADC within the ROI of lowest ADC were calculated.
A note was made of any difficulties in selecting the ROI, such as artifacts or small lesion size
(Figures 1-2). Following the analysis of T1-weighted images with and without contrast, patterns
of enhancement were described as heterogeneous, ring-like or diffuse.
FIGURE 1: Contrast-enhancing Oligodendroglioma
A contrast enhancing lesion in the right frontal lobe with significant mass effect. The darkest
area on apparent diffusion coefficient (ADC) (left), however, had a mean value of 1246.6 (>800).
The actual diagnosis is of grade II oligodendroglioma.
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FIGURE 2: Contrast-enhancing Glioblastoma Multiforme (GBM)
On apparent diffusion coefficient (ADC) sequence (left), the darkest area in the tumor region
had a mean ADC value of 363.8 which according to the results of the receiver operator curve
(ROC) represents high grade glioma. Contrast enhancement also favors the diagnosis.
Histopathological diagnosis was GBM.
Statistical analysis
All data were analyzed using SPSS v 17 (IBM, Chicago, Illinois, US). Frequencies of sample and
tumor characteristics were calculated. Analysis of variance (ANOVA) was used to measure
differences in mean ADCs of different tumor grades. Independent sample t-tests were used to
compare mean ADCs in low and high-grade tumors. A P value <0.05 was considered statistically
significant. Receiver operator curve (ROC) analyses were performed to determine whether
ADCs were predictors of high-grade tumors, including the sensitivity and specificity of ADC as a
predictor.
Results
The study included 48 patients with glioma, 34 males (70.8%) and 14 females (29.2%), of mean
age 40.59 ± 19.56 years. Fourteen patients were excluded because preoperative radiological
imaging results were unavailable, and four were excluded because their histopathology results
were inconclusive. Table 1 shows the baseline demographic and clinical characteristics of the
patients in this study.
Variables Statistics
Demographics Mean ± Std/ N (%)
Age (years) 40.56 ± 17.56
Gender  
     Male 34 (70.8)
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     Female 14 (29.2)
Tumor characteristics  
WHO Tumor grade  
     Low Grade 19 (39.6)
          I 5 (10.4)
          II 14 (29.2)
     High Grade 29 (60.4)
          III 11 (22.9)
          IV 18 (37.5)
Tumor pathology  
     Pilocytic Astrocytoma 5 (10.4)
     Diffuse astrocytoma II 1(2.08)
     Gemistocytic astrocytoma 1(2.08)
      Oligodendroglioma II 12(25)
     Anaplastic Astrocytoma 2 (4.16)
     Anaplastic Oligodendroglioma 8 (16.67)
     Anaplastic Oligoastrocytoma 1(2.08)
     Glioblastoma Multiforme 14(29.16))
     Gliosarcoma 4(8.3)
Enhancement Pattern  
Ring Enhancement 14(29.2)
Heterogeneous enhancement 27(56.3)
Diffuse 4(8.3)
No Enhancement 3(6.3)
TABLE 1: Patient Demographics and Clinical Characteristics
The numbers and percentages of patients with grade I–IV tumors are shown in Table 2. The
mean lowest ADC of the tumor region was significantly higher for grade I than for grade IV
lesions (653.20 ± 145.07 vs. 333.83 ± 295.47, p = 0.001). Patients were dichotomized into those
with high grade (III and IV) and low grade (I and II) gliomas. The mean lowest ADC of the tumor
region was significantly higher for low grade than high-grade gliomas (678.73 ± 208.52 vs.
373.75 ± 257.06, p <0.001).
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Tumor Grade Number (%) ADC min ± Std ADC lowest mean ± Std
Grade I 5 (10.4) *653.20±145.07 1111.20±253.88
Grade II 14 (29.2) 687.85±231.06 1011.05±303.175
Grade III 11 (22.9) 439.09±170.41 755.12±191.59
Grade IV 18 (37.5) 333.83±295.47 727.90±233.59
Low Grade Gliomas 19 (39.6) **678.73±208.52 1037.41±287.68
High Grade Gliomas 29(60.4) ***373.75±257.06  738.23 ±215.45
TABLE 2: Tumor Grades with ADC Values
Std: standard deviation; ADC: apparent diffusion coefficient.
*ANOVA test p value 0.001, **,*** t-test p value <0.001
ROC analysis showed that the area under the curve (AUC) for minimum ADC in the entire
tumor as a predictor of low grade glioma was 0.80 (95 % confidence interval (CI) 0.675–0.926, p
<0.001) and that the AUC for the mean lowest ADC sub-region was 0.80 (95% CI 0.66–0.937)
(Figure 3). A cut off of 800 calculated from the ROC curve was used to estimate the sensitivity
and specificity of ADC for high-grade gliomas (Table 3).
2018 Darbar et al. Cureus 10(3): e2284. DOI 10.7759/cureus.2284 6 of 10
               Tumor Grade  
ADC High Grade Low Grade Total
Low <800 18 3 21
High >800 11 16 27
Total 29 19 48
FIGURE 3: ROC Curve for Lowest Mean ADC as a Predictor of
High Grade Tumors
ADC: apparent diffusion coefficient; ROC: receiver operator curve.
TABLE 3: Sensitivity and Specificity Analysis for ADC
ADC: apparent diffusion coefficient.
Of the 48 tumors, three showed no enhancement on contrast, and one high-grade glioma
showed diffuse enhancement on scanning. All estimates of diagnostic accuracy were conducted
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within 95% CIs.
Discussion
The minimum ADC was significantly lower for high grade than for low-grade gliomas (373.75 ±
257.06 vs. 678.73 ± 208.52, p <0.001), and the minimum ADC for tumors had an AUC of 0.80 for
predicting low-grade gliomas. Previous studies assessing the role of ADC in predicting tumor
pathology [2, 8, 17] had several limitations, including small sample size and heterogeneous
pathology [18]. The study with the largest sample size involved 275 patients, including
subgroups with intra-axial lesions, and showed that ADC had good discriminatory value in
predicting grades of astrocytomas [18]. ADCs have also been used to distinguish GBMs from
lymphomas [19] and to reliably distinguish pilocytic astrocytomas from ependymomas and
medulloblastomas in pediatric patients [20]. The lowest ADCs for grade I pilocytic astrocytoma
in that study ranged from 800 to 2400, similar to our results [20]. However, that study did not
include other types of glioma. To our knowledge, our study is the largest to date on patients
with glioma and showed that ADC could distinguish among different tumor grades.
Although conventional imaging techniques of MRI and computed tomography (CT) have been
widely used to diagnose brain tumors, they are not optimal for distinguishing between high
grade and low-grade gliomas. Conventional MRI does not provide consistent information on
factors that help determine tumor grade, including tumor microvascularity, micronecrosis,
angiogenesis, and metabolism [21-22]. This inadequacy is also attributable to similarities in
contrast enhancement, peri-lesional edema, necrosis and mass effect which can lead to low-
grade gliomas being mistaken for higher grade ones and vice versa [21, 23]. According to Zhang
et al., one-third of non-enhancing gliomas turn out to be high-grade gliomas, while on the
other hand partial contrast enhancement is seen in around 20% of low-grade gliomas [21].
MRI in patients with GBM is markedly affected by tumor genetics and aggressive features,
including cellularity and microvasculature [4]. Those findings were based on the ADC map of
tumors, indicating that ADC maps can help in guiding the sampling of tumor regions, thereby
improving the quality and representativeness of these samples. A prospective study showing
the correlation between histologic features and ADCs can further validate these findings.
ADC is an appropriate imaging modality for prediction of tumor grades because of its capacity
to accurately differentiate between low and high-grade tumors. Lower ADC values in high-
grade gliomas are obtained due to increased cellularity of the tissue, while low-grade gliomas
with less cellularity, and presumably a higher water content in interstitial spaces, result in
increased ADC values [24].
Mean and minimum ADCs of the entire tumor, as well as the lowest mean ADC within a tumor,
have been used to determine tumor pathology and grade [25]. Our study, which evaluated the
minimum ADC of the entire tumor and the mean ADC of the subregion with greatest diffusion
restriction, found that the latter had a higher AUC. Because most of the gliomas showed
enhancement on contrast sequences, it may not discriminate among diagnostic grades.
In a recent study by Fawzy et al., diffusion MRI and ADC had a higher sensitivity, specificity,
and accuracy than conventional MRI in glioma grading [26]. Based on currently available data,
the pooled sensitivity and specificity of ADC maps calculated by Zhang et al. are 0.85 and 0.8,
respectively, which further conveys the practicality of using ADC for differentiating between
glioma grades [21].
Diffusion-weighted imaging and ADC, however, are not without pitfalls and limitations [27].
The images can be affected by artifacts, including motion and echo-planar imaging (EPI)
2018 Darbar et al. Cureus 10(3): e2284. DOI 10.7759/cureus.2284 8 of 10
artifacts and eddy currents. These limitations may be overcome by following standard protocols
and are less common in the imaging of the brain than other organs of the body [27-28].
Conclusions
Through this study, we aimed to analyze the potential of ADC in predicting tumor grade by
examining diffusion-weighted images and correlating ADC of gliomas with the WHO grade.
ADCs of tumor regions on preoperative MRI can discriminate between low and high-grade
gliomas with an AUC of 0.80, and low-grade gliomas have significantly higher mean lowest
ADCs than high-grade gliomas. ADCs greater than 800 are predictive of low-grade gliomas, with
a sensitivity of 84.5%. We hope that these findings shed light on the possibility of a greater role
of ADC in the representative sampling of tumor tissue, and believe that ADCs should be
routinely evaluated when planning surgery for glioma.
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